A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes ...

April 24 - A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes and weight-loss drugs Ozempic and Wegovy while a legal challenge ...

Novo Nordisk has become aware of several hundred units of Ozempic® (semaglutide) injection 1 mg distributed outside the Novo ...

SAP’s finance chief, Dominik Asam, hopes tariffs are a “wake-up call” that can kick-start Europe into building more tech ...

Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

“While there’s still a lot to learn, these findings show that regular intensity exercise, even at low intensity, could go a ...

Recent health news covers a range of topics, from misinformation about measles vaccines affecting American households to pharmaceutical companies like Merck adjusting profits due to tariff costs.

Companies are announcing significant investments in U.S. manufacturing in response to looming tariffs. An AstraZeneca ...

The MOU marks a significant step in strengthening the Kingdom’s healthcare sector and pharmaceutical manufacturing ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several times a year. Ciara Lee reports.

Along with the rest of the market, Novo Nordisk (NYSE:NVO) has been sinking this year – with losses approaching 30% ...